EyePoint Pharmaceuticals, Inc.

NASDAQ:EYPT

Biotechnology

Healthcare
$2.99 +1.98%

+$0.26 today

Market cap
$250.69M
Beta
1.75
P/E (TTM)
-4.2
EPS (TTM)
-$3.16
52W Low $7.94High $19.11

Volume 2.75M

Average 0.95M

EYPT Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

EyePoint Pharmaceuticals, Inc.NASDAQ: EYPT

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 86M shares rose 23.3% year over year, behind the +27.7% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 3.6% from the prior quarter. Over 3 fiscal years it compounded at +25.2% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +23.3% toward the trailing-twelve-month pace of +27.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
86M+3.6% QoQ
Last fiscal yearDec 2025
73.25M+30.1% YoY
LTMMar 2026
77.28M+27.7% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+23.3%——
1 year+30.1%——
3-year CAGR+25.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
73.25M USD
Year-over-year change
+30.1%
4-year CAGR
+26.3%

Weighted Avg Shares (Diluted) vs competitors

How EYPT compares with its peers on the latest reported figures

  • EYPT's LTM Mar 2026 weighted avg shares (diluted) of 77.28M shares is the 8th highest of the 11 companies compared; the peer median is 104.74M shares.
  • Its year-over-year change of +27.7% is the 4th highest of 11, against a peer median of +16.1%.
  • Over three fiscal years its annual growth of +25.2% compares with a peer median of +13.3%.
EYPT Competitors Peer median
Weighted Avg Shares (Diluted) for EYPT and competitors
Company Period LTM YoY 3-year CAGR
SVRASavara Inc.LTM Mar 2026227.14M +12.3%+13.3%
PRMEPrime Medicine, Inc.LTM Mar 2026153.89M +26.0%+15.2%
TNGXTango Therapeutics, Inc.LTM Sep 2026145.89M +32.5%+9.8%
PROKProKidney Corp.LTM Mar 2026135.66M +18.2%+29.6%
NRIXNurix Therapeutics, Inc.LTM Aug 2026108.1M +31.0%+21.3%
RZLTRezolute, Inc.LTM Mar 2026101.37M +55.6%+57.4%
KURAKura Oncology, Inc.LTM Mar 202687.97M +1.1%+9.4%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 202677.28M +27.7%+25.2%
KODKodiak Sciences Inc.LTM Sep 202660.16M +14.0%+0.6%
BCAXBicara Therapeutics Inc. Common StockLTM Mar 202656.24M +3.4%+1.8%
SEPNSepterna, Inc.LTM Sep 202645.24M +9.0%—
Peer median (excluding EYPT) 104.74M+16.1%+13.3%

Competitors are the stored peer set for EYPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue36.94M41.4M46.02M43.27M31.37M
Cost of Revenue8.18M8.33M4.63M3.71M2.07M
Gross Profit28.76M33.08M41.39M39.56M29.31M
Gross Margin77.9%79.9%89.9%91.4%93.4%
Research & Development28.5M49.64M64.66M132.93M221.04M
Selling, General & Admin53.08M60.32M51.79M52.49M51.7M
Operating Expenses84.04M132.72M116.45M185.42M272.74M
Depreciation & Amortization2.77M2.45M464K1.54M2.31M
EBITDA(50.15M)(96.62M)(69M)(129.23M)(229.34M)
EBITDA Margin-135.8%-233.4%-149.9%-298.6%-731.1%
Operating Income(55.28M)(99.64M)(75.07M)(145.85M)(243.43M)
Operating Margin-149.6%-240.6%-163.1%-337.1%-776.0%
Interest Income292K2.13M6.95M15.09M11.75M
Interest Expense5.5M3.19M1.25M14K(33K)
Other Income / Expenses(3.14M)(2.62M)4.36M15.07M11.75M
Income Before Tax(58.42M)(102.25M)(70.71M)(130.78M)(231.68M)
Pre-Tax Margin-158.1%-247.0%-153.7%-302.2%-738.5%
Income Tax Expense0083K90K279K
Net Income(58.42M)(102.25M)(70.8M)(130.87M)(231.96M)
Net Margin-158.1%-247.0%-153.8%-302.4%-739.4%
EPS (Basic)(2.03)(2.74)(1.82)(2.32)(3.17)
EPS (Diluted)(2.03)(2.74)(1.82)(2.32)(3.17)
Weighted Avg Shares28.76M37.32M38.9M56.3M73.25M
Weighted Avg Shares (Diluted)28.76M37.32M38.9M56.3M73.25M

EyePoint Pharmaceuticals, Inc.

NASDAQ:EYPT

Intrinsic Alpha fair value

Locked

Current Price

$2.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.